Pegloticase example sentences

"Pegloticase" Example Sentences

1. Pegloticase is a medication used to treat gout.
2. The doctor prescribed pegloticase for his severe gout attack.
3. Patients receiving pegloticase should be monitored closely for adverse reactions.
4. Pegloticase injections are administered intravenously.
5. The efficacy of pegloticase varies among patients.
6. Several studies have evaluated the safety profile of pegloticase.
7. Infusion reactions are a common side effect of pegloticase.
8. Pegloticase works by breaking down uric acid crystals.
9. Long-term use of pegloticase may lead to antibody formation.
10. The cost of pegloticase treatment can be substantial.
11. Alternatives to pegloticase include allopurinol and febuxostat.
12. Pegloticase is a last resort for some gout patients.
13. Research continues into improving the delivery method of pegloticase.
14. Understanding the mechanism of action of pegloticase is crucial.
15. Are there any contraindications to the use of pegloticase?
16. What are the potential benefits and risks associated with pegloticase?
17. The patient responded well to the pegloticase treatment.
18. Pegloticase treatment requires careful monitoring of kidney function.
19. Further research is needed to optimize the use of pegloticase.
20. This case study highlights the successful use of pegloticase in a refractory gout case.
21. Improper administration of pegloticase can lead to complications.
22. Many patients experience relief from severe gout symptoms with pegloticase.
23. The study concluded that pegloticase was effective in reducing uric acid levels.
24. How does pegloticase differ from other gout medications?
25. Pegloticase may not be suitable for all patients with gout.
26. With pegloticase, significant improvement in joint pain was observed.
27. Adverse events associated with pegloticase should be reported promptly.
28. The pharmaceutical company manufactures pegloticase under strict quality control.
29. Despite its effectiveness, pegloticase is not without limitations.
30. Pegloticase's high cost limits its accessibility for some patients.
31. They discontinued pegloticase due to severe allergic reactions.
32. The physician carefully weighed the risks and benefits of pegloticase.
33. Regular blood tests are necessary while on pegloticase therapy.
34. Pegloticase remains a valuable option for treatment-resistant gout.
35. Long-term studies are needed to fully understand the effects of pegloticase.
36. Improved patient education about pegloticase is crucial.
37. Is pegloticase a first-line treatment for gout?
38. The patient's response to pegloticase was closely monitored.
39. Pegloticase therapy often involves a multidisciplinary approach.
40. Pegloticase offers a new hope for individuals with severe, chronic gout.
41. What are the most common reasons for discontinuation of pegloticase?
42. The development of pegloticase was a significant advance in gout management.
43. Future research may focus on developing less immunogenic forms of pegloticase.
44. Pegloticase is administered by a trained healthcare professional.
45. This clinical trial investigates the efficacy and safety of pegloticase in a specific population.
46. Monitoring for infusion reactions is paramount during pegloticase administration.
47. The high price of pegloticase poses a significant barrier to access.
48. Pegloticase is a uricase enzyme.
49. The use of pegloticase has revolutionized the treatment of certain gout patients.
50. Before starting pegloticase, thorough assessment of kidney function is essential.